Novo Nordisk A/S $NVO Shares Sold by Moloney Securities Asset Management LLC

Moloney Securities Asset Management LLC decreased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 36.0% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 11,169 shares of the company’s stock after selling 6,289 shares during the period. Moloney Securities Asset Management LLC’s holdings in Novo Nordisk A/S were worth $771,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Revolve Wealth Partners LLC boosted its stake in shares of Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after purchasing an additional 200 shares during the period. GAMMA Investing LLC boosted its stake in Novo Nordisk A/S by 9.6% during the 1st quarter. GAMMA Investing LLC now owns 9,466 shares of the company’s stock valued at $657,000 after acquiring an additional 827 shares during the last quarter. Spire Wealth Management boosted its stake in Novo Nordisk A/S by 8.2% during the 1st quarter. Spire Wealth Management now owns 12,862 shares of the company’s stock valued at $893,000 after acquiring an additional 978 shares during the last quarter. Golden State Wealth Management LLC boosted its stake in Novo Nordisk A/S by 127.1% during the 1st quarter. Golden State Wealth Management LLC now owns 4,128 shares of the company’s stock valued at $287,000 after acquiring an additional 2,310 shares during the last quarter. Finally, Park Place Capital Corp boosted its stake in Novo Nordisk A/S by 26.1% during the 1st quarter. Park Place Capital Corp now owns 1,683 shares of the company’s stock valued at $117,000 after acquiring an additional 348 shares during the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

NVO has been the topic of a number of research analyst reports. Barclays reiterated an “equal weight” rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. BNP Paribas Exane raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 target price on the stock in a report on Wednesday, August 13th. Wall Street Zen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. Hsbc Global Res raised shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 1st. Finally, BNP Paribas raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a report on Wednesday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S has an average rating of “Moderate Buy” and a consensus price target of $76.00.

Novo Nordisk A/S Stock Down 0.4%

NVO stock opened at $53.02 on Friday. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $114.19. The firm’s 50-day simple moving average is $56.56 and its 200 day simple moving average is $62.39. The stock has a market cap of $236.74 billion, a PE ratio of 14.57, a price-to-earnings-growth ratio of 2.42 and a beta of 0.68.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, topping analysts’ consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The business had revenue of $11.69 billion for the quarter, compared to analysts’ expectations of $77.51 billion. As a group, sell-side analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were paid a dividend of $0.4119 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 22.53%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.